Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Efficacy of Uromune® Autovaccine in Recurrent Urinary Tract Infection Management: A Unicenter Retrospective Study in Reus, Spain

Simona Iftimie
ORCID logo ,
Paula Ladero-Palacio
,
Ana F. López-Azcona
,
Laia Pujol-Galarza
,
Antoni Pont-Salvadó
,
Xavier Gabaldó-Barrios
,
Jorge Joven
,
Jordi Camps
* ,
Antoni Castro
* ORCID logo ,
Mercè Pascual-Queralt
Version 1 : Received: 19 September 2024 / Approved: 19 September 2024 / Online: 19 September 2024 (15:38:21 CEST)

How to cite: Iftimie, S.; Ladero-Palacio, P.; López-Azcona, A. F.; Pujol-Galarza, L.; Pont-Salvadó, A.; Gabaldó-Barrios, X.; Joven, J.; Camps, J.; Castro, A.; Pascual-Queralt, M. Efficacy of Uromune® Autovaccine in Recurrent Urinary Tract Infection Management: A Unicenter Retrospective Study in Reus, Spain. Preprints 2024, 2024091534. https://doi.org/10.20944/preprints202409.1534.v1 Iftimie, S.; Ladero-Palacio, P.; López-Azcona, A. F.; Pujol-Galarza, L.; Pont-Salvadó, A.; Gabaldó-Barrios, X.; Joven, J.; Camps, J.; Castro, A.; Pascual-Queralt, M. Efficacy of Uromune® Autovaccine in Recurrent Urinary Tract Infection Management: A Unicenter Retrospective Study in Reus, Spain. Preprints 2024, 2024091534. https://doi.org/10.20944/preprints202409.1534.v1

Abstract

Introduction: Urinary tract infections (UTIs) are a significant global health issue, especially among women, with growing concerns related to antibiotic resistance and adverse effects. The Uromune® vaccine, a sublingual bacterial lysate, represents a promising therapeutic alternative by enhancing immune responses against uropathogens. Methods: This retrospective study, conducted at Hospital Universitari de Sant Joan de Reus from January 2017 to August 2022, evaluated the effectiveness of Uromune® in treating recurrent UTIs (rUTIs). Patients received personalized autovaccines administered as two sublingual puffs daily for three months. Clinical, microbiological, and demographic data were analyzed to assess treatment outcomes and identify recurrence-associated factors. Results: Forty-nine patients (mean age, 61 years, and 59.2% women) were included in the study. Uromune® treatment decreased UTI episodes, from 3.73 ± 0.97 the year before to 0.98 ± 1.36 (P < 0.001) the year after its administration. The number of patients who suffered three or more episodes per year dropped from 43 (87.7%) before the intervention to 7 (14.3%) afterward. The maximum effectiveness of the autovaccine was observed three months post-administration, with 44 patients not experiencing any UTI episodes. Regression analysis identified having had a urostomy, chronic kidney disease, and being immunosuppressed as predictors of recurrence. Conclusion: The Uromune® autovaccine effectively reduced the frequency of rUTIs and associated hospitalizations, offering substantial relief to patients. These findings support the integration of Uromune® into routine clinical practice as a viable alternative to conventional antibiotic treatments.

Keywords

antibiotic resistance; immunotherapy; recurrent urinary tract infections; sublingual bacterial lysate; Uromune® vaccine

Subject

Medicine and Pharmacology, Urology and Nephrology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.